Skip to main content
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. — Investor Relations & Filings

Ticker · APVO ISIN · US03835L2079 LEI · 529900UTQOXOZBMZFN24 US Professional, scientific and technical activities
Open in API
Filings indexed 684 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US APVO

About Aptevo Therapeutics Inc.

https://aptevotherapeutics.com/

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-27 English
8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)
Regulatory Filings Classification · 75% confidence The document is a U.S. SEC Form 8-K “Current Report” filed pursuant to the Securities Exchange Act, disclosing an “Other Event” (a press release) and attaching the press release as Exhibit 99.1. It does not contain financial statements itself, nor is it a management change, earnings release, dividend notice, or other specific category. As a generic SEC regulatory filing that does not fit a more specific category, it should be classified under Regulatory Filings (RNS).
2026-05-06 English
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing clinical trial results for Aptevo’s investigational therapy. It contains no financial statements, management changes, voting results, or regulatory report attachments. It is a standalone news announcement. This does not match any specific category like earnings release, annual/interim report, or M&A activity. As a general corporate announcement, it falls into the fallback category of Regulatory Filings (RNS).
2026-03-27 English
8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 18, 2026, reporting the submission of matters to a vote of security holders at a Special Meeting. It details the voting results for three proposals, including approval of an amended certificate of incorporation, stock issuance approval under a Standby Equity Purchase Agreement, and authorization to adjourn the meeting. The content is focused on official voting results from a shareholder meeting, not a full report or financial data. The document length is 4246 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-02-19 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.